Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Panacea Biotec's share price for the quarter that ended in Mar. 2026 was ₹296.15. Panacea Biotec's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 61 Mil. Therefore, Panacea Biotec's market cap for the quarter that ended in Mar. 2026 was ₹18,139 Mil.
Panacea Biotec's quarterly market cap
declined
from Sep. 2025 (₹24,889 Mil) to Dec. 2025 (₹23,046 Mil) and
declined
from Dec. 2025 (₹23,046 Mil) to Mar. 2026 (₹18,139 Mil).
Panacea Biotec's annual market cap
increased
from Mar. 2024 (₹7,430 Mil) to Mar. 2025 (₹26,990 Mil) but then
declined
from Mar. 2025 (₹26,990 Mil) to Mar. 2026 (₹18,139 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Panacea Biotec's Enterprise Value for Today is ₹31,796 Mil.
Panacea Biotec (BOM:531349) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Panacea Biotec Market Cap Related Terms
Panacea Biotec Market Cap Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Panacea Biotec's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Market Cap distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Panacea Biotec's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Biotec (BOM:531349) has a Market Cap of ₹32,965 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Panacea Biotec and its competitors. According to the industry distribution chart, Panacea Biotec ranks #488 out of 1423 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Panacea Biotec's Market Cap too high?
Panacea Biotec's current Market Cap is ₹32,965 Mil. Based on the distribution chart, Panacea Biotec ranks #488 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #488 out of 1423 companies for Market Cap. This puts Panacea Biotec in the upper half of its industry. The industry median Market Cap is 114.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.24, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Panacea Biotec and its competitors. For the Biotechnology industry, the median Market Cap is 114.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Biotec's current Market Cap is ₹32,965 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹538.20 — trading 49.5% above its estimated fair value. The current Market Cap is ₹32,965 Mil. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Market Cap is ₹32,965 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued.
The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92.
GuruFocus considers Panacea Biotec to be Significantly Overvalued.
Key valuation signals for BOM:531349:
Market Cap: ₹32,965 Mil
GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score
Get the complete analysis for BOM:531349
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
